Cabozantinib used as first-line therapy prolongs PFS for metastatic RCCOctober 15, 2016Genitourinary CancerRenal Cell Carcinoma
Adjuvant sunitinib offers DFS edge in high-risk RCCOctober 14, 2016Genitourinary CancerRenal Cell Carcinoma
In favorable intermediate-risk prostate cancer, brachytherapy alone sufficesOctober 6, 2016Genitourinary Cancer
A positive attitude in prostate cancer challenges: finding hope and optimismSeptember 28, 2016Genitourinary CancerPatient & Survivor Care
10-year follow-up: Localized prostate cancer treatments offer similar efficacySeptember 21, 2016Genitourinary Cancer
FDA modifies dosage regimen for nivolumabSeptember 19, 2016Lung CancerGenitourinary CancerLymphoma & Plasma Cell DisordersMelanomaRenal Cell Carcinoma
New anticancer drugs linked to increased costs, life expectancySeptember 12, 2016Genitourinary CancerPractice ManagementLung CancerBreast CancerLymphoma & Plasma Cell Disorders
Drug combo shows promise for non–clear cell renal cell carcinomaSeptember 6, 2016Genitourinary CancerRenal Cell Carcinoma
Study supports extending docetaxel therapy in metastatic castration-resistant prostate cancerSeptember 2, 2016Genitourinary Cancer
Prostate cancer incidence continues to decrease after recommendation against screeningSeptember 1, 2016Genitourinary CancerPreventive Care
Active surveillance may be feasible for some advanced RCC patientsAugust 12, 2016Genitourinary CancerRenal Cell Carcinoma
